Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00240344
First received: October 16, 2005
Last updated: August 29, 2011
Last verified: August 2011
  Purpose

The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.


Condition Phase
Hypercholesterolemia
Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: REALISTIC: Protocol for an Observational Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New EAS LDL-C Target Goal

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 2650
Study Start Date: September 2004
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care

Criteria

Inclusion Criteria:

  • High risk patients
  • High doses of other statins
  • LDL-C known, starts with Crestor 10 mg
  • Permission to use patient data by AstraZeneca (AZ)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00240344

  Show 75 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Netherlands Medical Director, MD AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00240344     History of Changes
Other Study ID Numbers: NL401142, REALISTIC
Study First Received: October 16, 2005
Last Updated: August 29, 2011
Health Authority: European Union: European Medicines Agency

Keywords provided by AstraZeneca:
High risk patients
Crestor
Rosuvastatin
LDL cholesterol
observational

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on September 18, 2014